FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2511598328> ?p ?o ?g. }

• W2511598328 endingPage "116" @default.
• W2511598328 startingPage "107" @default.
• W2511598328 abstract "Background Most breast cancer (BC) tumors ≤10 mm have an excellent prognosis. The subgroups with a higher risk for distant recurrence requiring adjuvant systemic therapy are not precisely defined in current international guidelines. Patients and Methods The OBSERVATOIRE DES PETITS CANCERS DU SEIN HER2 +/− (ODISSEE) study was a prospective, multicenter, cohort study that aimed to describe the daily adjuvant management and outcome of 616 patients with unifocal, invasive pT1a-b pN0 nonmetastatic BC who underwent surgery. Results At the time of diagnosis, the median age of patients was 61 years. Tumor was detected on imaging or during a screening program in 397 patients (64.6%). Most patients (96%) underwent conservative surgery with sentinel node biopsy (89%), completed with axillary lymph node dissection in 15%. At inclusion, 82% of tumors were pT1b, 73% were pN0 (i−), 53% were Scarff–Bloom–Richardson Grade I, 91% were estrogen receptor (ER)-positive, 5% overexpressed/amplified HER2, and 5% were triple negative (TNBC). Adjuvant treatments were radiotherapy (95%), hormone therapy (82%), chemotherapy (7%), and trastuzumab (3.5%). In patients with TNBC and HER2-positive BC, chemotherapy and trastuzumab (if needed) were administered in 45% and 68%, respectively. After 5 years of follow-up, 7 patients had contralateral BC, 7 had locoregional recurrence, and 1 had distant metastasis. At 5 years, overall survival, disease-free survival, and recurrence-free survival were: 98.4% (96.9%-99.1%), 94.7% (92.4%-96.3%), and 97.1% (95.2%-98.2%), respectively. Conclusion This prospective cohort study showed that in France, the routine practice in pT1a-b pN0 breast cancers follows international standard guidelines for practice including conservative surgery followed by radiotherapy and endocrine therapy for ER-positive patients. Adjuvant chemotherapy with or without trastuzumab was used but their benefit in breast cancer of ≤10 mm remains controversial." @default.
• W2511598328 created "2016-09-16" @default.
• W2511598328 creator A5006422634 @default.
• W2511598328 creator A5006696190 @default.
• W2511598328 creator A5011227048 @default.
• W2511598328 creator A5020758672 @default.
• W2511598328 creator A5021462010 @default.
• W2511598328 creator A5043914694 @default.
• W2511598328 creator A5048484257 @default.
• W2511598328 creator A5051524865 @default.
• W2511598328 creator A5054491719 @default.
• W2511598328 creator A5058739883 @default.
• W2511598328 creator A5058791215 @default.
• W2511598328 creator A5061340891 @default.
• W2511598328 creator A5061803573 @default.
• W2511598328 creator A5071971525 @default.
• W2511598328 creator A5074406174 @default.
• W2511598328 creator A5088635711 @default.
• W2511598328 date "2017-04-01" @default.
• W2511598328 modified "2023-10-08" @default.
• W2511598328 title "Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study" @default.
• W2511598328 cites W1571344193 @default.
• W2511598328 cites W1741754986 @default.
• W2511598328 cites W1948838904 @default.
• W2511598328 cites W198122113 @default.
• W2511598328 cites W1988622440 @default.
• W2511598328 cites W1991117132 @default.
• W2511598328 cites W2011751936 @default.
• W2511598328 cites W2045216597 @default.
• W2511598328 cites W2065020864 @default.
• W2511598328 cites W2068228843 @default.
• W2511598328 cites W2074643669 @default.
• W2511598328 cites W2074908331 @default.
• W2511598328 cites W2076672860 @default.
• W2511598328 cites W2077117803 @default.
• W2511598328 cites W2095633632 @default.
• W2511598328 cites W2095799175 @default.
• W2511598328 cites W2097541112 @default.
• W2511598328 cites W2102486244 @default.
• W2511598328 cites W2106366706 @default.
• W2511598328 cites W2113450161 @default.
• W2511598328 cites W2115331726 @default.
• W2511598328 cites W2128458647 @default.
• W2511598328 cites W2136270722 @default.
• W2511598328 cites W2147577114 @default.
• W2511598328 cites W2150815608 @default.
• W2511598328 cites W2152121934 @default.
• W2511598328 cites W2166034342 @default.
• W2511598328 cites W2173858545 @default.
• W2511598328 cites W2436152463 @default.
• W2511598328 doi "https://doi.org/10.1016/j.clbc.2016.08.007" @default.
• W2511598328 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27856201" @default.
• W2511598328 hasPublicationYear "2017" @default.
• W2511598328 type Work @default.
• W2511598328 sameAs 2511598328 @default.
• W2511598328 citedByCount "1" @default.
• W2511598328 countsByYear W25115983282021 @default.
• W2511598328 crossrefType "journal-article" @default.
• W2511598328 hasAuthorship W2511598328A5006422634 @default.
• W2511598328 hasAuthorship W2511598328A5006696190 @default.
• W2511598328 hasAuthorship W2511598328A5011227048 @default.
• W2511598328 hasAuthorship W2511598328A5020758672 @default.
• W2511598328 hasAuthorship W2511598328A5021462010 @default.
• W2511598328 hasAuthorship W2511598328A5043914694 @default.
• W2511598328 hasAuthorship W2511598328A5048484257 @default.
• W2511598328 hasAuthorship W2511598328A5051524865 @default.
• W2511598328 hasAuthorship W2511598328A5054491719 @default.
• W2511598328 hasAuthorship W2511598328A5058739883 @default.
• W2511598328 hasAuthorship W2511598328A5058791215 @default.
• W2511598328 hasAuthorship W2511598328A5061340891 @default.
• W2511598328 hasAuthorship W2511598328A5061803573 @default.
• W2511598328 hasAuthorship W2511598328A5071971525 @default.
• W2511598328 hasAuthorship W2511598328A5074406174 @default.
• W2511598328 hasAuthorship W2511598328A5088635711 @default.
• W2511598328 hasConcept C121608353 @default.
• W2511598328 hasConcept C126322002 @default.
• W2511598328 hasConcept C141071460 @default.
• W2511598328 hasConcept C143998085 @default.
• W2511598328 hasConcept C188816634 @default.
• W2511598328 hasConcept C2777982462 @default.
• W2511598328 hasConcept C2779786085 @default.
• W2511598328 hasConcept C2780212769 @default.
• W2511598328 hasConcept C509974204 @default.
• W2511598328 hasConcept C530470458 @default.
• W2511598328 hasConcept C71924100 @default.
• W2511598328 hasConcept C72563966 @default.
• W2511598328 hasConceptScore W2511598328C121608353 @default.
• W2511598328 hasConceptScore W2511598328C126322002 @default.
• W2511598328 hasConceptScore W2511598328C141071460 @default.
• W2511598328 hasConceptScore W2511598328C143998085 @default.
• W2511598328 hasConceptScore W2511598328C188816634 @default.
• W2511598328 hasConceptScore W2511598328C2777982462 @default.
• W2511598328 hasConceptScore W2511598328C2779786085 @default.
• W2511598328 hasConceptScore W2511598328C2780212769 @default.
• W2511598328 hasConceptScore W2511598328C509974204 @default.
• W2511598328 hasConceptScore W2511598328C530470458 @default.
• W2511598328 hasConceptScore W2511598328C71924100 @default.
• W2511598328 hasConceptScore W2511598328C72563966 @default.

• next